Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Sorafenib
Related studies linked through entity extraction aliases.
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE1
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
- Status
- COMPLETED
- Phase
- PHASE1
Circulating Tumor Cells and Tumor DNA in HCC and NET
- Status
- COMPLETED
- Phase
- N/A
Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.
- Status
- COMPLETED
- Phase
- PHASE3
Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail
- Status
- COMPLETED
- Phase
- PHASE4
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
- Status
- TERMINATED
- Phase
- PHASE3
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
- Status
- COMPLETED
- Phase
- PHASE3
Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
- Status
- TERMINATED
- Phase
- NA
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
- Status
- WITHDRAWN
- Phase
- PHASE2
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE4
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
- Status
- COMPLETED
- Phase
- PHASE2
Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors
- Status
- WITHDRAWN
- Phase
- NA
Metformin Plus Sorafenib for Advanced HCC
- Status
- UNKNOWN
- Phase
- PHASE2
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Status
- UNKNOWN
- Phase
- PHASE2
Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study
- Status
- COMPLETED
- Phase
- PHASE1